Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Morning! If you’re still wondering “What the heck happened with Moderna?” the latest episode of the video series STATus Report spells it out quite nicely. Also, a KFF poll shows 1 in 8 Americans have used a GLP-1 by now, Kura wins FDA approval for its AML drug, and more.

The need-to-know this morning

Belgian drugmaker Lundbeck made an unsolicited, $23-per-share offer for Avadel Pharmaceuticals . The new bid tops the $20-per-share acquisition offer made by Alkermes last month. Alkermes said it is considering its options for Avadel in light of the higher Lundbeck offer.

Anavex Life Sciences said advisers to the European Medicines Agency issued a “

See Full Page